'Multi-target' immune therapy improves outcomes of severe lupus nephritis

July 02, 2008

A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a report in the October Journal of the American Society of Nephrology (JASN).

"In our study, multi-target therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects," comments Dr. Lei-Shi Li of the Research Institute of Nephrology of Jinling Hospital, Nanjing University School of Medicine in Nanjing,China.

The study included 40 patients with severe lupus nephritis. Lupus nephritis is inflammation of the kidneys occurring in patients with the immune system disease systemic lupus erythematosus (SLE). All patients had "class V+IV" disease, meaning widespread inflammation and decreasing function of the kidneys. "This is a severe form of lupus nephritis that is traditionally treated with a single immunosuppressant drug, but the efficacy is very poor," says Dr. Li. "We considered that, since the impact of severe SLE on the kidney involves various parts of the immune system, it is necessary to treat the different immune targets with a combination of immunosuppressant drugs."

One group of patients received this "multi-target" therapy, consisting of the immunosuppressant drugs tacrolimus and mycophenolate mofetil-commonly used as anti-rejection drugs in transplant patients-plus a steroid. The other group received standard treatment with a single immunosuppressant drug (cyclophosphamide).

The complete remission rate, with recovery of normal kidney function, was about four times higher among patients receiving the three-drug combination. "For patients receiving multi-target therapy, the complete remission rate reached 65 percent at nine months, versus only 15 percent under traditional therapy," says Dr. Li.

Some patients in both groups had partial remission, with some return of kidney function. Overall, 95 percent of patients in the multi-target therapy group had partial or complete remission, compared to 55 percent with single-drug therapy. The rate of most adverse effects was also lower with multi-target therapy.

Systemic lupus erythematosus is an autoimmune disorder, in which the immune system attacks healthy organs and tissues. By reducing immune system activity, treatment with immunosuppressant drugs has improved most outcomes for patients with SLE. However, class V+IV lupus nephritis continues to be a major problem-it has a poor response to traditional treatments and can lead to permanent kidney damage. "The prognosis is very poor, so it is important for us to develop a new regimen for the treatment of this type of lupus nephritis," says Dr. Li.

Using a combination of drugs that affect different immune targets, multi-target therapy improves the chances of remission for patients with severe lupus nephritis. "The therapeutic effect of our multi-target therapy is apparently superior to traditional therapy for inducing complete remission of Class V+IV lupus nephritis, and also bears good tolerance under relatively lower dosages," Dr. Li adds.

The authors stress that their study is only preliminary. The study includes a small group of patients from a single hospital, with a relatively short follow-up time. Larger randomized trials with longer follow-up are required.

American Society of Nephrology

---

---

	Lupus Nephritis (Oxford Clinical Nephrology) by Edmund J. Lewis (Author), Melvin M. Schwartz (Author), Stephen M. Korbet (Author), Tak Mao Chan (Author) Severe inflammation of the kidney can indicate the serious, negative prognosis of lupus nephritis when present in conjunction with systemic lupus erythematosus (SLE), a chronic autoimmune connective tissue disease that can affect any part of the body, most often harming the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. This book pulls together in one comprehensive reference the current knowledge regarding the inherited and immunologic abnormalities that have been identified in SLE, with specific reference to the development of renal disease and the way in which these factors may impact upon the chronic care of these patients. Since publication of the first edition in 1999, the discipline of medicine has experienced some revolutionary changes in the...
	Lupus Nephritis: Frontiers and Challenges (Immunology and Immune System Disorders) by Hussein A. Sheashaa (Author), Tarek M. Abbas (Author), Fatma E. Moustafa (Author), Khaled Mahmoud (Author), Amgad El-agroudy (Author) Aupus nephritis (AN) is a major cause of morbidity and mortality, affecting over half of systemic Aupus erythematosis (SAE) patients, both adult and paediatric. The accelerating advances in molecular and cellular immunology have paved the way for development biologic agents that target specific pathways that contribute to the inflammatory response, but there is no strong evidence of their safety and efficacy. Moreover, the increased risk of renal allograft thrombosis and recurrence of Aupus nephritis constitute a substantial risk that should be thoroughly explored. This book explores the major advances that necessitate the evolution of basic and clinical research in order to investigate the management of this syndrome.
	Lupus Nephritis (Oxford Clinical Nephrology Series) by Edmund J. Lewis (Editor), Melvin M. Schwartz (Editor), Stephen M. Korbet (Editor) The presence of severe nephritis is a serious adverse prognostic feature of systemic lupus erythematosus (SLE). The book summarises the remarkable amount of information that has been generated in the quest for relief of patients, mostly young women, who have the unfortunate circumstances of having developed severe lupus nephritis. Lupus Nephritis pulls together in one reference source the current knowledge regarding the inherited and immunologic abnormalities which have been identified in SLE with specific reference to the development of renal disease and the way in which these factors may impact upon the chronic care of these patients. This book is also an up-to-date resource regarding the diagnosis and management of a broad range of abnormalities which are encountered in the population...
	The Official Patient's Sourcebook on Lupus Nephritis by James N. Parker (Author), Icon Health Publications (Author) This sourcebook has been created for patients who have decided to make education and Internet-based research an integral part of the treatment process. Although it gives information useful to doctors, caregivers and other health professionals, it also tells patients where and how to look for information covering virtually all topics related to lupus nephritis, from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on lupus nephritis. Following an introductory chapter, the sourcebook is organized into...
	The First Year--Lupus: An Essential Guide for the Newly Diagnosed by Nancy C. Hanger (Author) Lupus affects an estimated 1.5 million people in the U.S.—90 percent of whom are women—but due to the diversity of its symptoms and severity, it remains one of the most difficult conditions to identify and diagnose. In the tradition of the other titles in the First Year™ series, The First Year™—Lupus uses a unique approach—guiding readers through their first seven days following diagnosis, then the next three weeks of their first month, and finally the next eleven months of their first year—to provide answers and advice that will help everyone newly diagnosed with lupus come to terms with their condition and the lifestyle changes that accompany it. Starting with the day of diagnosis, Hanger provides vital information about the nature of lupus, choosing the right doctors,...
	Race impacts prognosis, biology of lupus nephritis. (Further SLE Studies Urged).: An article from: Skin & Allergy News by Elizabeth Mechcatie (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on April 1, 2002. The length of the article is 577 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Race impacts prognosis, biology of lupus nephritis. (Further SLE Studies Urged). Author: Elizabeth Mechcatie Publication: Skin & Allergy News (Magazine/Journal) Date: April 1, 2002 Publisher: International Medical News Group Volume: 33 Issue: 4 Page: 28(1) Distributed by Thomson...
	Lupus Nephritis: Pathophysiology, Diagnosis, and Collaborative Management.: An article from: Nephrology Nursing Journal by D. Michelle Smith (Author), E. Michelle Fortune-Faulkner (Author), Brenda L. Spurbeck (Author) This digital document is an article from Nephrology Nursing Journal, published by Jannetti Publications, Inc. on April 1, 2000. The length of the article is 8362 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. From the author: Lupus nephritis (LN) is a complex disease. The pathophysiology involves the glomerulus and mesangium, and its manifestations are exhibited in extensive renal lesions. The World Health Organization (WHO) has developed a classification system to assist clinicians in understanding the severity of renal involvement. The diagnosis of systemic lupus erythematosus (SLE) and LN can be...
	Oral mycophenolate mofetil looks promising for lupus nephritis.(Nephrology): An article from: Internal Medicine News by Sharon Worcester (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on January 1, 2006. The length of the article is 468 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Oral mycophenolate mofetil looks promising for lupus nephritis.(Nephrology) Author: Sharon Worcester Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2006 Publisher: Thomson Gale Volume: 39 Issue: 1 Page: 18(1) Distributed by Thomson...
	Lupus Nephritis - Pipeline Review, Q4 2010 by Global Markets Direct (Author) Lupus Nephritis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Lupus Nephritis Pipeline Review, Q4 2010”, provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Nephritis. “Lupus Nephritis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put...
	Lupus Nephritis - Pipeline Review, Q1 2011 by Global Markets Direct (Author) Lupus Nephritis - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, Q1 2011', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Nephritis. 'Lupus Nephritis - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by...